MOL MED 20 (SUPPLEMENT 1), S20-S23, 2014| GRUNDY| S21 times normal levels.
Patients with FH carry mutations that impair the synthesis of LDL receptors (7). Kinetic …

Since the groundbreaking Scandanavian Simvastatin Survival Study (4S) trial over a decade
ago, the HMG-CoA reductase inhibitors, or Statins, have been central in the prevention of …

The ultimate goal of lipid-lowering therapy is to reduce the risk of atherosclerotic
cardiovascular disease (ASCVD). Current cholesterol guidelines1 recommend …

Statins are, to date, the most powerful cholesterol lowering drugs. In brief, they inhibit 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, which is a key enzyme in the …

The review by Smith and Grundy (1) of the American College of Cardiology/American Heart
Association Cholesterol Treatment Guideline is helpful, but recommendations for statin …

Hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or
“statins,” have been extremely efficacious in decreasing low-density lipoprotein (LDL) …

In late 2004, the British government decided to allow a lipid-lowering agent to be sold as an
over-the-counter medication. In contrast, the US Food and Drug Administration recently …

1327 Comparative Study of 3 Strong Statins ferase (ALT) was observed more frequently with
atorvastatin than with the other 2 statins. Although this significant difference diluted toward …

Almost since they were first introduced, statin drugs have been recognized to have effects
beyond their potent low-density lipoprotein (LDL)-lowering abilities. These “pleitropic” effects …

With the strong correlation between the development of coronary heart disease and
elevated levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) …